The UK Government has outlined the implications of "no deal" for medicines regulation in the UK.
In a series of briefing notes (this link will take you away from our website), the UK Government has outlined possible consequences of the United Kingdom leaving the European Union without a deal.
One of our members’ key concerns since the UK’s decision to leave the EU in June 2016, has been the potential for delay in access of medicines and medical devices manufactured in the EU that support them to live well.
The briefing notes, which have been summarised by the ALLIANCE, outline that:
- In the event of “no deal”, the Medicines and Healthcare products Regulatory Agency (MHRA) would take on the functions currently undertaken by the EU for medicines on the UK market.
- The UK will recognise medical devices approved for the EU market and CE (European Conformity)-marked.
- The EU Organ Directives and EU Tissues and Cells Directives would no longer apply to the UK – but safety standards would not change.
We would like to hear from ALLIANCE members, individuals or organisations, who are concerned about the potential of a “no deal” Brexit and what it will mean for medicines, medical devices or any other matter related to support and services for people living with long term conditions, disabled people and unpaid carers. Members can contact Andrew Strong by email on email@example.com or by telephone on 0141 404 0231 to discuss further.